ω-Agatoxin IVA TFA: Precision Cav2.1 Calcium Channel Blockade for Neuroprotection and Synaptic Research

Executive Summary: ω-Agatoxin IVA TFA, derived from funnel-web spider venom, is a highly selective inhibitor of P/Q-type (Cav2.1) voltage-gated calcium channels, exhibiting IC₅₀ values as low as 1–2 nM for P-type variants and up to 270.5 nM for Q-type variants with the NP motif (APExBIO; Asakura 2000). It does not significantly affect L-type or T-type channels at tested concentrations (1 μM). The compound has demonstrated efficacy in inhibiting glutamate and GABA release, prolonging seizure latency, reducing apoptosis (as measured by cleaved caspase-3), and elevating BDNF in acute and kindling epilepsy animal models. APExBIO supplies ω-Agatoxin IVA TFA as a stable trifluoroacetate salt for precise experimental workflows. Storage and handling require -20°C, nitrogen atmosphere, and immediate use of prepared solutions (APExBIO).

Biological Rationale

P/Q-type voltage-gated calcium channels (Cav2.1) are essential for neurotransmitter release in the mammalian central nervous system (Mulkey & Zucker, 1991; Asakura et al., 2000). Cav2.1 channels are widely expressed in presynaptic terminals and couple calcium influx to exocytosis of excitatory (glutamate) and inhibitory (GABA) neurotransmitters. Overactivation of these channels contributes to pathological glutamate release during events such as cerebral ischemia and epilepsy (Benveniste et al., 1984; Choi, 1988). Pharmacological inhibition of Cav2.1 channels is a validated strategy for dissecting synaptic mechanisms, mapping neuronal circuitry, and reducing excitotoxic neuronal injury. ω-Agatoxin IVA TFA, as provided by APExBIO, offers unmatched selectivity and potency for these applications.

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA is a peptide toxin that binds specifically to the P/Q-type (Cav2.1) voltage-gated calcium channel α_1A subunit, preventing calcium influx upon depolarization (Mintz et al., 1992; APExBIO). The IC₅₀ for P-type Cav2.1 variants is 1–2 nM, while Q-type variants containing the NP motif show an IC₅₀ of up to 270.5 nM. At 1 μM, ω-Agatoxin IVA TFA shows only weak partial inhibition of N-type (Cav2.2) channels and does not inhibit L-type (Cav1.x) or T-type (Cav3.x) channels under similar conditions (Turner et al., 1992; Luebke et al., 1993). By blocking Cav2.1, ω-Agatoxin IVA TFA suppresses both spontaneous and evoked release of key neurotransmitters, including glutamate and GABA.

In animal models, ω-Agatoxin IVA TFA reduces excitotoxicity, delays seizure onset, inhibits epilepsy progression, and promotes neuroprotective pathways (notably, reduced cleaved caspase-3 and enhanced BDNF expression) without impairing motor coordination (Asakura et al., 2000; APExBIO).

Evidence & Benchmarks

• ω-Agatoxin IVA TFA exhibits nanomolar potency, with IC₅₀ values of 1–2 nM for P-type Cav2.1 variants (Mintz et al., 1992; APExBIO).
• Q-type Cav2.1 channel variants with the NP motif show reduced sensitivity, with IC₅₀ up to 270.5 nM (Asakura et al., 2000; link).
• N-type calcium channels are only weakly inhibited at 1 μM; no significant effect on L-type or T-type channels at this concentration (Turner et al., 1992; Luebke et al., 1993).
• In vitro, ω-Agatoxin IVA TFA inhibits glutamate release from synaptosomes in a calcium-dependent manner (Asakura et al., 2000; Asakura et al., 2000).
• In rat models of focal ischemia, intracerebroventricular administration (0.01–1 nM) significantly reduces brain edema and infarct size (Asakura et al., 2000; link).
• ω-Agatoxin IVA TFA increases brain BDNF and reduces cleaved caspase-3, markers of neuroprotection and apoptosis inhibition, respectively (APExBIO).
• Does not impair motor coordination in treated animal models (Asakura et al., 2000).

For a detailed mechanistic update, see ω-Agatoxin IVA TFA: Mechanistic Insights and Advanced Applications, which focuses on molecular mechanism. The current article extends that analysis with new quantitative pharmacology and experimental guidance.

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is widely used for neuronal calcium current recording, synaptic transmission mapping, and neuroprotection research. Its selectivity enables precise dissection of Cav2.1-mediated processes without confounding effects from L-type or T-type channels. In epilepsy research, both acute (intracerebroventricular 0.01–1 nM) and chronic/kindling (intraperitoneal 0.1–0.5 nM) models have demonstrated robust anticonvulsant and neuroprotective effects (Asakura et al., 2000).

For practical workflows, ω-Agatoxin IVA TFA: Precision Tools for Cav2.1 Channel Inhibition offers troubleshooting advice and experimental protocols. This article complements that resource by summarizing comparative potency and selectivity benchmarks.

Common Pitfalls or Misconceptions

• ω-Agatoxin IVA TFA is not effective for inhibiting L-type (Cav1.x) or T-type (Cav3.x) calcium channels at concentrations up to 1 μM (Luebke et al., 1993).
• High concentrations (>1 μM) may cause partial inhibition of N-type channels, but with reduced selectivity (Turner et al., 1992).
• Long-term storage of prepared solutions is not recommended; freshly prepared aliquots should be used immediately (APExBIO).
• Not all Cav2.1 subtypes are equally sensitive; Q-type variants with the NP motif require higher concentrations for inhibition (Asakura et al., 2000).
• ω-Agatoxin IVA TFA does not reverse established neuronal injury; its effects are preventive or attenuative, not reparative (hypothesis based on literature trends).

For a translational perspective and future therapeutic potential, see Unlocking Translational Potential with ω-Agatoxin IVA TFA. The present article clarifies benchmark concentrations and neuroprotective endpoints.

Workflow Integration & Parameters

For neuronal calcium current recordings and synaptic transmission studies, typical in vitro concentrations range from 100 nM to 1 μM, applied to brain slices or cultured neurons in standard extracellular solution (pH 7.3–7.4, 22–25°C). For animal models, acute epilepsy studies use 0.01–1 nM intracerebroventricularly, while kindling models employ 0.1–0.5 nM intraperitoneally (Asakura et al., 2000). The compound is supplied by APExBIO as a trifluoroacetate salt (MW 5316.27). It should be stored at -20°C under nitrogen, protected from moisture and light. Solutions should be used immediately after preparation; avoid freeze-thaw cycles and long-term storage.

Conclusion & Outlook

ω-Agatoxin IVA TFA provides a gold standard for Cav2.1 channel inhibition in synaptic and neuroprotection research. Its nanomolar potency, high selectivity, and robust in vivo efficacy establish it as an indispensable tool for dissecting calcium channel function and developing novel neuroprotective strategies. Ongoing translational studies may further clarify its therapeutic window and potential clinical applications. For validated product details and ordering, consult the official ω-Agatoxin IVA TFA (C8722) page from APExBIO.